Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 28, 2010, Pages 12617-12622

  Bradner, James E ^a,b   Mak, Raymond ^a   Tanguturi, Shyam K ^a   Mazitschek, Ralph ^a   Haggarty, Stephen J ^a   Ross, Kenneth ^a   Chang, Cindy Y ^a   Bosco, Jocelyn ^a   West, Nathan ^a,b   Morse, Elizabeth ^a,b   Lin, Katherine ^c   Shen, John Paul ^a   Kwiatkowski, Nicholas P ^a   Gheldof, Nele ^d   Dekker, Job ^d   DeAngelo, Daniel J ^b   Carr, Steven A ^a   Schreiber, Stuart L ^a,e,f   Golub, Todd R ^a,b,f   Ebert, Benjamin L ^a,b,c,g  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^e HARVARD UNIVERSITY   (United States)

^f HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^g HARVARD STEM CELL INSTITUTE   (United States)

Author keywords

Acetylation; Chromatin; Hemoglobinopathies; Histone

Indexed keywords

GAMMA GLOBIN; HEMOGLOBIN; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT;

ARTICLE; CHROMATIN STRUCTURE; CONTROLLED STUDY; ERYTHROID CELL; GENE EXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RNA INTERFERENCE; SICKLE CELL;

AFRICA; CELL DIFFERENTIATION; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HUMANS; INFANT; PROTEIN ISOFORMS; RNA INTERFERENCE;

EID: 77955463320     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1006774107     Document Type: Article

References (34)

1. Weatherall D, Akinyanju O, Fucharoen S, Olivier N, Musgrove P (2006) Disease Control Priorities in Developing Countries, eds Jamieson D, et al. (Oxford University Press, Oxford, Washington), pp 663-680.
2. Bunn HF (1997) Pathogenesis and treatment of sickle cell disease. N Engl J Med 337: 762-769. (Pubitemid 27417977)
3. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG (1984) Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 310: 869-873.
4. Platt OS, et al. (1984) Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74:652-656. (Pubitemid 14054015)
5. Charache S, et al., Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (1995) Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332:1317-1322.
6. Steinberg MH, et al. (2003) Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 289: 1645-1651.
7. Steinberg MH (1999) Management of sickle cell disease. N Engl J Med 340:1021-1030.
8. Bank A (2006) Regulation of human fetal hemoglobin: New players, new complexities. Blood 107:435-443.
9. Drissen R, et al. (2004) The active spatial organization of the beta-globin locus requires the transcription factor EKLF. Genes Dev 18:2485-2490. (Pubitemid 39362891)
10. Palstra RJ, et al. (2003) The beta-globin nuclear compartment in development and erythroid differentiation. Nat Genet 35:190-194.
11. Patrinos GP, et al. (2004) Multiple interactions between regulatory regions are required to stabilize an active chromatin hub. Genes Dev 18:1495-1509.
12. Menzel S, et al. (2007) A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 39:1197-1199.
13. Lettre G, et al. (2008) DNA polymorphisms at the BCL11A, HBS1L-MYB, and betaglobin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci USA 105:11869-11874.
14. Sankaran VG, et al. (2008) Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 322:1839-1842.
15. Uda M, et al. (2008) Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci USA 105:1620-1625.
16. Sankaran VG, et al. (2009) Developmental and species-divergent globin switching are driven by BCL11A. Nature 460:1093-1097.
17. Peck D, et al. (2006) A method for high-throughput gene expression signature analysis. Genome Biol 7:R61. (Pubitemid 44269480)
18. Saunthararajah Y, et al. (2003) Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102:3865-3870.
19. Liakopoulou E, et al. (1995) Stimulation of fetal hemoglobin production by short chain fatty acids. Blood 86:3227-3235.
20. Marianna P, et al. (2001) Valproic acid, trichostatin and their combination with hemin preferentially enhance gamma-globin gene expression in human erythroid liquid cultures. Haematologica 86:700-705.
21. Gabbianelli M, et al. (2003) HbF reactivation in sibling BFU-E colonies: Synergistic interaction of kit ligand with low-dose dexamethasone. Blood 101:2826-2832.
22. Sealy L, Chalkley R (1978) The effect of sodium butyrate on histone modification. Cell 14:115-121. (Pubitemid 8340439)
23. Cao H, Stamatoyannopoulos G, Jung M (2004) Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 103:701-709.
24. Swank RA, Skarpidi E, Papayannopoulou T, Stamatoyannopoulos G (2003) The histone deacetylase inhibitor, trichostatin A, reactivates the developmentally silenced gamma globin expression in somatic cell hybrids and induces gamma gene expression in adult BFUe cultures. Blood Cells Mol Dis 30:254-257.
25. Witt O, et al. (2003) Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 101:2001-2007. (Pubitemid 36237607)
26. Haggarty SJ, Koeller KM, Wong JC, Butcher RA, Schreiber SL (2003) Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. Chem Biol 10:383-396.
27. Dekker J, Rippe K, Dekker M, Kleckner N (2002) Capturing chromosome conformation. Science 295:1306-1311.
28. Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299.
29. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges. Cancer Lett 280:233-241.
30. Bradner JE, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6:238-243.
31. Stegmaier K, et al. (2007) Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 4:e122.
32. Ferranti P, Mamone G, Malorni A (2000) Preparation and mass spectrometric analysis of S-nitrosohemoglobin. Methods Mol Biol 146:147-165.
33. Miele A, Gheldof N, Tabuchi TM, Dostie J, Dekker J (2006) Current Protocols in Molecular Biology, eds Ausubel FM, et al. (John Wiley & Sons, Hoboken, NJ), pp 2111-2120.
34. Dostie J, et al. (2006) Chromosome Conformation Capture Carbon Copy (5C): A massively parallel solution for mapping interactions between genomic elements. Genome Res 16:1299-1309.